Biolines Weekender is BioNJ’s weekly e-newsletter featuring the latest happenings in R&D, as well as the incredible innovation coming from New Jersey’s robust life sciences ecosystem.
Welcome to the newly designed BioLines Weekender. Our new format allows for easier reading on mobile devices. And, our user-friendly links allow you to easily register for BioNJ events, as well as add them to your Outlook calendar. To access full articles, please click on the article’s title….... Read the full article
Welcome to an early edition of BioLines Weekender as this Friday, the BioNJ Team is headed to BioNJ’s CEO Summit at the Bridgewater Marriott. An industry trademark event, the CEO Summit will bring together nearly 300 biotech/pharma C-Suite leaders and their teams, investors, entrepreneurs, academics and other...... Read the full article
In tribute to our industry as well as New Jersey, BioNJ and our 4th Annual CEO Summit, BioNJ’s President and CEO, Debbie Hart; Lt. Governor Kim Guadagno; along with Board members and other industry members had the honor yesterday of ringing the opening bell of the NASDAQ..... Read the full article
Many of New Jersey’s innovative biopharma companies advanced recently on their way to new FDA drug approvals, including BioNJ Members Scynexis, Soligenix and Eli Lilly & Co., giving fresh hope to Patients and their families ... Read the full article
In this week’s edition of the BioLines Weekender we introduce a new section entitled “Economic Developments.” In addition to highlighting the numerous companies moving to the Garden State, we will be spotlighting those expanding their footprint, such as BioNJ Member Allergan. .... Read the full article
BioNJ Member press releases and upcoming events.
Ewing/Lambertville, NJ – Imbue Creative has moved their headquarters into the first floor of the striking circa 1860 Italian Revival building at 71 North Main Street in Lambertville, after spending over six months lovingly restoring it…..Read the full article
Ewing/Lambertville, NJ – The first floor of the striking circa 1860 Italian Revival building at 71 North Main Street in Lambertville, most recently the home of MacDonald Kitchen and Bath Designs, has stood empty for three years. Soon, it will be the new home of Imbue Creative, a branding and creative services agency that is in the process of revitalizing the building….Read the full article
May 3, 2016 – Acumen BioPharma Launches New Business Unit, Expands Capabilities into Continuous Pharmaceutical Manufacturing
PRINCETON, NJ – “The launch of a new business unit tremendously expands our capabilities in the analysis, engineering and implementation of continuous pharmaceutical manufacturing,” states Daisy Rivera-Muzzio….Read the full article
CRANBURY, NJ – “We’re proud of our ISO 17025 accreditation as it reflects the broad scope of our capabilities. Also, it’s gratifying to know that we’re one of the very few labs, nationally, to hold accreditation for Elemental Impurities.” Quantex Laboratories’ President and CEO, James Menoutis, PhD, reacts to the lab’s accreditation achievement…Read the full article
Englewood Cliffs, N.J./March 23, 2016 – The executive talend solutions firm JBK Associates International has opened an office in Geneva, Switzerland, as part of the firm’s expanding international practice. Under the leadership of Elaine L. Arozarena …Read the full article
Englewood Cliffs, N.J./March 17, 2016 – The Women’s Venture Fund (WVF) has appointed Julie B. Kampf to its board of directors …Read the full article
Englewood Cliffs, N.J./December 16, 2015 – Julie B. Kampf, CEO & Chief Possibilities Officer of the executive talent solutions firm JBK Associates International, has been named one of New York Business Journal’s 2016 Women of Influence Award honorees. Kampf is among 79 New York metropolitan area …Read the full article
Triple Play: Why life sciences industry has bright future in N.J. | NJBIZ We asked John for three reasons why the future is bright for life sciences in New Jersey and here is what he had to say…Read the full article
EWING, N.J., Nov. 10, 2015 — Celator Pharmaceuticals, Inc. announced the presentation of positive results from its CombiPlex® technology platform applied to drug combinations incorporating molecularly targeted agents (MTAs) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics… Read the full article
Oct. 21, 2015 – Celator® Pharmaceuticals Announces VYXEOS™ (CPX -351) Shows No QT/QTc Interval Prolongation in an Intensive QT/QTc Study
EWING, N.J., Oct. 21, 2015 — Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) today announced that a Phase 2 pharmacokinetic and pharmacodynamics (PK/PD) study evaluating the effects of VYXEOS™ (CP-X351) on cardiac depolarization/repolarization has concluded and VYXEOS did not prolong the QT/QTc interval… Read the full article
Interested in reading more? View BioNJ Members in the News Archive.